Transgene Biotek Share Price

2.94-0.03 (-1.01%)

BSE

Closed
As On:
As On: 12 Jun, 2026, 03:40 PM IST

Sector: Hospitals & All...
Industry: Medical Equipment ...

STOCK SCORE

Unlock Scores

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	-
High	-
Low	-
Prev Close	-
Volume	-
VWAP(₹)	-

Share Price	Value
Today/Current/Last	-2.94
Previous Day	-2.97

Transgene Biotek Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Transgene Biotek Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	0.20	0.05	0.05	0.05	0.12
Total Income Growth (%)	275.05	3.22	6.67	-58.85	-0.82
Total Expenses	0.38	0.15	0.18	0.24	0.64
Total Expenses Growth (%)	148.45	-12.49	-25.58	-62.99	234.48
EBIT	-0.18	-0.10	-0.12	-0.19	-0.52
EBIT Growth (%)	-	-	-	-	-
Profit after Tax (PAT)	-0.46	-0.37	-0.39	-0.43	-0.71
PAT Growth (%)	-	-	-	-	-
EBIT Margin (%)	-88.16	-184.04	-235.04	-380.20	-433.83
Net Profit Margin (%)	-223.58	-685.87	-735.61	-876.16	-592.77
Basic EPS (₹)	-0.06	-0.05	-0.05	-0.06	-0.09

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	0.20	0.05	0.05	0.05	0.12
Total Income Growth (%)	275.05	3.22	6.67	-58.85	0.00
Total Expenses	0.38	0.15	0.18	0.24	0.64
Total Expenses Growth (%)	148.45	-12.49	-25.58	-62.99	234.48
EBIT	-0.18	-0.10	-0.12	-0.19	-0.52
EBIT Growth (%)	-	-	-	-	-
Profit after Tax (PAT)	-0.46	-0.37	-0.39	-0.43	-0.71
PAT Growth (%)	-	-	-	-	-
EBIT Margin (%)	-88.16	-184.04	-235.04	-380.20	-433.83
Net Profit Margin (%)	-223.58	-685.87	-735.61	-876.16	-592.77
Basic EPS (₹)	-0.06	-0.05	-0.05	-0.06	-0.09

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	0.36	1.04	0.42	0.23	0.30
Total Revenue Growth (%)	-65.42	150.05	81.19	-22.98	-31.44
Total Expenses	2.01	1.72	1.07	6.24	10.70
Total Expenses Growth (%)	17.07	60.31	-82.80	-41.70	-1.55
Profit after Tax (PAT)	-1.65	-0.68	-0.66	-6.01	-10.40
PAT Growth (%)	-	-	-	-	-
Operating Profit Margin (%)	-280.63	-166.12	-224.09	0.00	0.00
Net Profit Margin (%)	-782.62	-259.34	-279.05	0.00	0.00
Basic EPS (₹)	-0.22	-0.09	-0.09	-0.79	-1.37

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	0.36	1.04	0.42	0.23	0.30
Total Revenue Growth (%)	-65.42	150.05	81.19	-22.98	-31.44
Total Expenses	2.01	1.72	1.07	6.24	10.70
Total Expenses Growth (%)	17.07	60.31	-82.80	-41.70	-1.55
Profit after Tax (PAT)	-1.65	-0.68	-0.66	-6.01	-10.40
PAT Growth (%)	-	-	-	-	-
Operating Profit Margin (%)	-280.63	-166.12	-224.09	0.00	0.00
Net Profit Margin (%)	-782.62	-259.34	-279.05	0.00	0.00
Basic EPS (₹)	-0.22	-0.09	-0.09	-0.79	-1.37

All figures in Rs Cr, unless mentioned otherwise

Insights

PAT: Troublesome Times
Company has posted a loss of Rs 0.46 cr for the 4th consecutive quarter. (Source: Consolidated Financials)
Topline Contraction
Sales de-grew by 65.42%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	143.66	144.09	142.33	142.36	147.10
Total Assets Growth (%)	-0.30	1.24	-0.02	-3.22	-6.24
Total Liabilities	135.28	134.06	131.62	130.99	129.72
Total Liabilities Growth (%)	0.91	1.86	0.48	0.98	-3.65
Total Equity	8.38	10.03	10.71	11.37	17.38
Total Equity Growth (%)	-16.48	-6.38	-5.77	-34.58	-21.86
Current Ratio (x)	0.08	0.10	0.10	0.09	0.08
Total Debt to Equity (x)	2.05	1.45	1.31	1.15	0.69
Contingent Liabilities	0.00	408.74	0.55	0.99	0.99

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	33.76	34.20	32.44	32.48	37.22
Total Assets Growth (%)	-1.29	5.43	-0.12	-12.74	-20.79
Total Liabilities	42.96	41.75	39.31	38.68	37.42
Total Liabilities Growth (%)	2.90	6.21	1.63	3.37	-11.60
Total Equity	-9.20	-7.55	-6.87	-6.21	-0.20
Total Equity Growth (%)	-	-	-	-	-104.29
Current Ratio (x)	0.08	0.10	0.10	0.09	0.08
Total Debt to Equity (x)	-1.86	-1.92	-2.04	-2.11	-60.99
Contingent Liabilities	0.00	203.57	0.55	0.99	0.99

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	-0.01	1.20	0.00	2,305.00	0.09
Net Cash used in Investing Activities	0.15	-1.70	-	-0.01	-0.10
Net Cash flow from Financing Activities	-0.36	0.78	-	-	-
Net Cash Flow	-0.22	0.28	0.00	-0.01	-0.01
Closing Cash & Cash Equivalent	0.06	0.28	0.01	0.00	0.02
Closing Cash & Cash Equivalent Growth (%)	-78.65	3,592.21	152.29	-79.82	-37.44
Total Debt/ CFO (x)	-1,516.53	12.14	3,043.70	0.01	139.69

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	-0.01	1.20	0.00	2,305.00	0.10
Net Cash used in Investing Activities	0.15	-1.70	-	-0.01	-0.10
Net Cash flow from Financing Activities	-0.36	0.78	-	-	-
Net Cash Flow	-0.22	0.28	0.00	-0.01	9,484.00
Closing Cash & Cash Equivalent	0.06	0.28	0.01	0.00	0.02
Closing Cash & Cash Equivalent Growth (%)	-78.65	3,592.21	152.29	-79.82	6.69
Total Debt/ CFO (x)	-1,516.53	12.14	3,043.70	0.01	125.21

All figures in Rs Cr, unless mentioned otherwise

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	-19.73	-6.74	-6.11	-52.85	-59.86
Return on Capital Employed (%)	-0.45	-0.32	-0.40	-4.41	-7.37
Return on Assets (%)	-1.15	-0.46	-0.46	-4.22	-7.07
Interest Coverage Ratio (x)	-0.37	-1.40	-3.36	-4.84	-1.11
Asset Turnover Ratio (x)	0.00	0.00	0.00	0.00	0.00
Price to Earnings (x)	-9.08	-37.74	-95.24	-3.14	-2.63
Price to Book (x)	1.79	2.53	5.76	1.66	1.57
EV/EBITDA (x)	-81.50	-116.56	-174.31	-36.45	-156.30
EBITDA Margin (%)	-186.36	-130.37	-184.80	-1,592.36	-290.36

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	0.00	0.00	0.00	0.00	0.00
Return on Capital Employed (%)	-2.87	-2.00	-2.45	-26.34	-36.18
Return on Assets (%)	-4.89	-1.97	-2.02	-18.49	-27.94
Interest Coverage Ratio (x)	-0.37	-1.40	-3.36	-4.84	-1.11
Asset Turnover Ratio (x)	0.01	0.01	0.01	0.00	0.00
Price to Earnings (x)	-9.08	-37.74	-95.24	-3.14	-2.63
Price to Book (x)	-1.63	-3.36	-8.98	-3.04	-138.85
EV/EBITDA (x)	-81.50	-116.56	-174.31	-36.47	-156.87
EBITDA Margin (%)	-186.36	-130.37	-184.80	-1,591.94	-289.36

Insights

Losing Shareholder's Money
Company has reported a negative ROE for 3 consecutive years. (Source: Consolidated Financials)

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Transgene Biotek	-13.48	2.65	-19.73	-0.45	-1.15	15.97	-280.63	-782.62	-0.22	0.08	2.05	-1,516.53
Nureca Ltd	106.80	1.23	1.15	3.43	1.06	9.30	4.26	1.41	2.11	8.32	0.00	0.22
Denis Chem Lab	12.13	1.11	9.18	13.67	6.73	4.34	7.00	4.62	6.06	2.70	0.05	1.01
Shree Pacetronix	16.70	2.90	17.36	25.02	12.22	2.24	21.35	14.53	8.66	2.71	0.15	0.92
Constronics Infra	18.49	1.26	6.78	6.78	4.27	284.65	7.91	5.80	2.25	3.32	0.41	4.86
Add More

Annual Ratios (%)

Choose from Peers

Bandaram Pharma Pack
Kretto Syscon
GKB Ophthalmics
Centenial Surg
Span Divergent

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Transgene Biotek Stock Performance	-1.01	-5.47	-1.67	15.75	-29.67	-25.00	-26.50
Nureca Ltd Stock Performance	1.41	-13.55	-10.41	-20.00	-7.07	-29.54	-85.26
Denis Chem Lab Stock Performance	2.08	-2.26	-6.73	-7.77	-28.81	-5.32	31.13
Shree Pacetronix Stock Performance	0.64	2.98	-5.59	7.69	79.72	1.97	1184.40
Constronics Infra Stock Performance	-1.25	-14.36	-22.19	-16.56	-24.29	0.00	0.00
Add More

Category	No. of Shares	Percentage
Promoters	1,64,27,902	23.64 %
Pledge	0	0.00 %
Others	5,93,42,098	76.36 %

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	23.64	23.64	23.64	23.64
Pledge	0.00	0.00	0.00	0.00
FII	0.00	0.00	0.00	0.00
DII	0.00	0.00	0.00	0.00
Mutual Funds	0.00	0.00	0.00	0.00
Others	76.36	76.36	76.36	76.36

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Board Meeting
Audited Results
May 15, 2026
Board Meeting
Quarterly Results
Jan 28, 2026
General Meeting
A.G.M
Dec 08, 2025

Board Meetings

Announced on	Meeting on
May 15, 2026	May 29, 2026
Audited Results
Jan 28, 2026	Feb 13, 2026
Quarterly Results
Oct 31, 2025	Nov 14, 2025
Quarterly Results
Jul 30, 2025	Aug 07, 2025
Quarterly Results
Apr 28, 2025	May 07, 2025
Audited Results

Dividends
No Data Available
Bonus
No Data Available
Splits
No Data Available
Rights
Announced on Ex-Date
Apr 13, 1995 -
Rights ratio: 3 share for every 5 held at a price of Rs 30.0

Announced on	Ex-Date
Apr 13, 1995	-
Rights ratio: 3 share for every 5 held at a price of Rs 30.0

AGM/EGM Meetings

Announced on	Meeting on
Dec 08, 2025	Dec 30, 2025
A.G.M
Nov 12, 2024	Dec 05, 2024
Book closure from Nov 29, 2024 to Dec 5, 2024
Nov 16, 2023	Dec 30, 2023
A.G.M.
Aug 24, 2020	Sep 30, 2020
Book closure from Sep 26, 2020 to Sep 29, 2020
Aug 28, 2019	Sep 30, 2019
Book closure from Sep 27, 2019 to Sep 29, 2019

About Transgene Biotek

Transgene Biotek Ltd., incorporated in the year 1990, is a Small Cap company (having a market cap of Rs 22.28 Crore) operating in Hospitals & Allied Services sector.

Transgene Biotek Ltd. key Products/Revenue Segments include Sale of services for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs .20 Crore, up 275.05 % from last quarter Total Income of Rs .05 Crore and up 69.91 % from last year same quarter Total Income of Rs .12 Crore. Company has reported net profit after tax of Rs -.46 Crore in latest quarter.

The company’s top management includes Dr.K Koteswara Rao, Mr.Santosh Kumar, Mrs.Sujana Kadiam, Mrs.Swetha Marri, Mr.Chowdari Prasad, Mrs.Ankita Jain. Company has Manisha Dubey & Associates as its auditors. As on 31-03-2026, the company has a total of 7.58 Crore shares outstanding.

Transgene Biotek Share Price Today is Rs. 2.94. On previous day, the Transgene Biotek Share Price (NSE) closed at Rs. 2.97, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 23.64% of the stake in Transgene Biotek shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Transgene Biotek stocks was 0.0% as compared to 0.0% in Dec 2025 with null of 0.0%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.0% as compared to 0.0% in Dec 2025 with null of 0.0%. Out of the total DII holdings in Transgene Biotek shares 0.0% was held by mutual funds. The rest including public held is 0.0%. Transgene Biotek stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Transgene Biotek Dividend: Ever since 1990, Transgene Biotek dividends has been paid out around 0 times. As on 12 Jun, 2026, 03:40 PM IST, The overall dividend yield for Transgene Biotek stands at 0.0%. The last dividend paid was on null (Rs. null). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. -0.22.

Transgene Biotek Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 0.2 Cr. of sales and 275.05% of quarterly net profit, there have been multiple ups and downs in the Transgene Biotek stock prices in the past few weeks. For example, Transgene Biotek stock price on 5th of June 2026 was around Rs. 3.11. Transgene Biotek share price now stands at an average of Rs. 2.94. Judging by last week's performance, stock is in down trend.

Transgene Biotek has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Transgene Biotek share.

Historical Prices and Performance:
Transgene Biotek, incorporated in 1990 is a Small Cap company (with a market cap of Rs. 22.28) operating in Hospitals & Allied Services sector.
The Return of Equity (ROE) in last five financial years given by Transgene Biotek stock was -19.73%, -6.74%, -6.11%, -52.85% and -59.86% respectively.
The Transgene Biotek share gave a 3 year return of -29.16% as compared to Nifty 50 which gave a return of 26.99%.
Transgene Biotek announced 0.0% final dividend on null.

Key Metrics:
PE Ratio of Transgene Biotek is -13.48
Prices/Sales Ratio of Transgene Biotek is 73.33
Price/Book Ratio of Transgene Biotek is 2.65

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. The PE ratio and PB Ratio of the company are among its competitors stand at -13.48 and 2.65 respectively.

Leadership of Transgene Biotek :
Ankita Jain is Co. Secretary & Compl. Officer
Chowdari Prasad is Chief Financial Officer
K Koteswara Rao is Chairman & Managing Director
Santosh Kumar is Director
Swetha Marri is Director
Sujana Kadiam is Director

Industry

Medical Equipment & Accessories

Key Indices Listed On

-

Address

Plot Nos. 69 & 70,Anrich Industrial Area,Sangareddy Dist., Telangana - 502325

Contact

info@transgenebiotek.com

http://www.transgenebiotek.com

PE Ratio(x)	-13.48
EPS - TTM(₹)	-0.22
MCap(₹ Cr.)	22.28
MCap Rank	50
PB Ratio(x)	2.65
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	5.26
52W Low(₹)	1.83
MCap/Sales	73.33
Beta(1 Month)	-0.50
BV/Share(₹)	1.11

1 Day	-1.01%
1 Month	-6.67%
3 Months	13.51%
1 Year	-30.66%
3 Years	-29.16%
5 Years	-40.85%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Transgene Biotek Share Price

Key Metrics